Payment overview · 2025
General Payments
$694.34
27 reported records · 10 companies
Healthcare provider profile · identity verified
Aijaz Khan, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · OCEANSIDE, NY · NPI 1912984063
Verified facts
What the public records show
CMS Open Payments records show Aijaz Khan, M.D. received $694.34 in general payments during 2025 across 27 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 26.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 489 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $182.84 | 26.3% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $106.06 | 15.3% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $81.65 | 11.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $65.28 | 9.4% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $59.23 | 8.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $57.92 | 8.3% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $54.91 | 7.9% | 2 | 2025 |
| Cumberland Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.85 | 4.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.78 | 4.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.82 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $694.34 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $182.84 | 8 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $106.06 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $81.65 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $65.28 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $65.28 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $65.28 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $59.23 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $57.92 | 3 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $54.91 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $46.65 | 2 | 2025 |
Source payment records
|
|||||
| KRISTALOSE Normalized: kristalose |
Drug | Cumberland Pharmaceuticals, Inc. | $32.85 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.78 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.78 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $23.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 175 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
175 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
36 | 35 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
175 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
489 | 68 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 594 | 133 |
| Atorvastatin Calcium | Atorvastatin Calcium | 593 | 144 |
| Levothyroxine Sodium | Levothyroxine Sodium | 527 | 104 |
| Metoprolol Succinate | Metoprolol Succinate | 522 | 124 |
| Eliquis | Apixaban | 489 | 68 |
| Furosemide | Furosemide | 473 | 96 |
| Gabapentin | Gabapentin | 392 | 55 |
| Losartan Potassium | Losartan Potassium | 376 | 97 |
| Metformin Hcl | Metformin Hcl | 325 | 77 |
| Simvastatin | Simvastatin | 320 | 77 |
| Escitalopram Oxalate | Escitalopram Oxalate | 318 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 296 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 246 | 52 |
| Potassium Chloride | Potassium Chloride | 245 | 39 |
| Omeprazole | Omeprazole | 226 | 79 |
| Famotidine | Famotidine | 224 | 66 |
| Warfarin Sodium | Warfarin Sodium | 210 | suppressed |
| Januvia | Sitagliptin Phosphate | 195 | 20 |
| Mirtazapine | Mirtazapine | 182 | 26 |
| Jardiance | Empagliflozin | 175 | 29 |
| Divalproex Sodium | Divalproex Sodium | 174 | 17 |
| Lisinopril | Lisinopril | 173 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 165 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 161 | 49 |
| Alprazolam | Alprazolam | 150 | 43 |
| Prednisone | Prednisone | 150 | 43 |
| Hydralazine Hcl | Hydralazine Hcl | 144 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 141 | 40 |
| Trazodone Hcl | Trazodone Hcl | 141 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 138 | 17 |
| Tramadol Hcl | Tramadol Hcl | 129 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 56 |
| Zolpidem Tartrate | Zolpidem Tartrate | 123 | 25 |
| Allopurinol | Allopurinol | 118 | 24 |
| Donepezil Hcl | Donepezil Hcl | 117 | 19 |
| Atenolol | Atenolol | 109 | 26 |
| Levetiracetam | Levetiracetam | 109 | 17 |
| Carvedilol | Carvedilol | 104 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 103 | 29 |
| Clonazepam | Clonazepam | 101 | 18 |
| Xarelto | Rivaroxaban | 101 | 14 |
| Lorazepam | Lorazepam | 97 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 93 | 29 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 92 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 92 | 69 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 91 | 15 |
| Latanoprost | Latanoprost | 90 | 19 |
| Azithromycin | Azithromycin | 84 | 71 |
| Baclofen | Baclofen | 82 | 14 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 81 | 22 |
| Santyl | Collagenase Clostridium Hist. | 79 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 74 | 17 |
| Memantine Hcl | Memantine Hcl | 73 | 13 |
| Ezetimibe | Ezetimibe | 71 | 14 |
| Ketoconazole | Ketoconazole | 70 | 15 |
| Ramipril | Ramipril | 70 | 16 |
| Risperidone | Risperidone | 69 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 39 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 62 | suppressed |
| Meloxicam | Meloxicam | 62 | 25 |
| Nifedipine Er | Nifedipine | 61 | 13 |
| Sertraline Hcl | Sertraline Hcl | 61 | 22 |
| Sodium Chloride | 0.9 % Sodium Chloride | 61 | 23 |
| Clonidine Hcl | Clonidine Hcl | 60 | suppressed |
| Methylprednisolone | Methylprednisolone | 60 | 50 |
| Montelukast Sodium | Montelukast Sodium | 60 | 18 |
| Diazepam | Diazepam | 59 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 59 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 58 | 48 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 17 |
| Tradjenta | Linagliptin | 56 | suppressed |
| Nystatin | Nystatin | 53 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | suppressed |
| Glipizide Er | Glipizide | 51 | 14 |
| Hydrocortisone | Hydrocortisone | 51 | 16 |
| Celecoxib | Celecoxib | 50 | 22 |
| Diltiazem 24hr Er | Diltiazem Hcl | 50 | suppressed |
| Glimepiride | Glimepiride | 50 | 17 |
| Metformin Hcl Er | Metformin Hcl | 48 | 17 |
| Mupirocin | Mupirocin | 48 | 21 |
| Buspirone Hcl | Buspirone Hcl | 47 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 47 | 38 |
| Enalapril Maleate | Enalapril Maleate | 46 | 13 |
| Finasteride | Finasteride | 45 | 21 |
| Ozempic | Semaglutide | 45 | suppressed |
| Synthroid | Levothyroxine Sodium | 45 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 28 |
| Divalproex Sodium Er | Divalproex Sodium | 43 | suppressed |
| Gemfibrozil | Gemfibrozil | 43 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 12 |
| Alendronate Sodium | Alendronate Sodium | 42 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 42 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 42 | 15 |
| Lactulose | Lactulose | 41 | 13 |
| Digoxin | Digoxin | 40 | suppressed |
| Procrit | Epoetin Alfa | 40 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 40 | suppressed |
| Amantadine | Amantadine Hcl | 39 | suppressed |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 25 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | 11 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 36 | 35 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 36 | suppressed |
| Torsemide | Torsemide | 35 | suppressed |
| Carbamazepine Er | Carbamazepine | 34 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Repaglinide | Repaglinide | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 32 | suppressed |
| Valsartan | Valsartan | 32 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 31 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Cephalexin | Cephalexin | 28 | 18 |
| Budesonide | Budesonide | 27 | suppressed |
| Movantik | Naloxegol Oxalate | 27 | suppressed |
| Primidone | Primidone | 27 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Ingrezza | Valbenazine Tosylate | 26 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 18 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 26 | suppressed |
| Clonidine | Clonidine | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 24 | suppressed |
| Cholestyramine Light | Cholestyramine | 24 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 22 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Tobramycin | Tobramycin | 22 | 20 |
| Calcitriol | Calcitriol | 21 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 21 | 14 |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Silodosin | Silodosin | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Valproic Acid | Valproic Acid | 21 | suppressed |
| Alphagan P | Brimonidine Tartrate | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 20 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 16 |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Pimozide | Pimozide | 18 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 17 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 12 |
| Anastrozole | Anastrozole | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Nystop | Nystatin | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Triazolam | Triazolam | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 15 | suppressed |
| Erythromycin | Erythromycin Base | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Lacosamide | Lacosamide | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Hydroxyurea | Hydroxyurea | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Permethrin | Permethrin | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Abilify Maintena | Aripiprazole | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Olanzapine Odt | Olanzapine | 12 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 12 | suppressed |
| Alogliptin | Alogliptin Benzoate | 11 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Clozapine | Clozapine | 11 | suppressed |
| Dextrose In Water | Dextrose 5 % In Water | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 11 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $694.34 · 27 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ABRYSVO, CAPLYTA, COMIRNATY, JARDIANCE, KRISTALOSE, Leqembi, MOUNJARO, Ozempic, PREVNAR 20, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, WATCHMAN FLX, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error